Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 9/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364363 | 0.93 | ESR2 (0.48) | ESR2TAS2R8MAP3K5NR1H2CDK5 | |
| SCHEMBL20364347 | 0.91 | TAS2R8 (0.49) | ESR2TAS2R8MAP3K5NR1H2MKNK1 | |
| SCHEMBL20364356 | 0.90 | MAP3K5 (0.41) | ESR2TAS2R8ABCB1MAP3K5NAMPT | |
| SCHEMBL20367121 | 0.89 | ABCB1 (0.44) | ESR2TAS2R8ABCB1MAP3K5NAMPT | |
| SCHEMBL20364350 | 0.88 | TAS2R8 (0.49) | ESR2TAS2R8MAP3K5NR1H2 | |
| SCHEMBL20364357 | 0.88 | MAP3K5 (0.41) | ESR2MAP3K5NR1H2MAPK1MKNK1 | |
| SCHEMBL20367330 | 0.86 | ABCB1 (0.44) | TAS2R8ABCB1MAP3K5NR1H2 | |
| SCHEMBL20364337 | 0.86 | ESR2 (0.46) | ESR2TAS2R8MAP3K5NR1H2 | |
| SCHEMBL20364364 | 0.85 | ESR2 (0.53) | ESR2TAS2R8MAP3K5NAMPTNR1H2 | |
| SCHEMBL20364355 | 0.85 | TAS2R8 (0.47) | TAS2R8MAP3K5NAMPTCDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | ESR2 620/4885TAS2R8 2479/4885ABCB1 1642/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | ESR2 620/4885TAS2R8 2479/4885ABCB1 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.